Helixgate

Helixgate

Uncategorized

UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy

News of the submission, which would be the first for UniQure’s closely watched treatment, comes as the therapy faces an uncertain future in the U.S. 

Read More

Published

on

News of the submission, which would be the first for UniQure’s closely watched treatment, comes as the therapy faces an uncertain future in the U.S. 

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Sanofi wins type 1 diabetes nod for Tzield after requesting to revoke CNPV

Sanofi wins type 1 diabetes nod for Tzield after requesting to revoke CNPV

Published

on

Sanofi makes no mention of the Commissioner’s National Priority Voucher. Tzield was awarded the ticket in October 2025, but Sanofi requested withdrawal from the program after former CDER head Tracy Beth Høeg reportedly expressed skepticism of the drug.​ ​Read More

Continue Reading

Uncategorized

Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic disease

Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic disease

Published

on

Rhythm Pharmaceuticals’ Imcivree reduced fat—while boosting muscle—in patients with Prader-Willi syndrome.​ ​Read More

Continue Reading

Uncategorized

Lilly sees quick return on $2.3B Ajax buy as blood cancer drug shows early efficacy

Published

on

Eli Lilly’s new JAK2 inhibitor—which it obtained from the recent acquisition of Ajax Therapeutics—reduced spleen volume by more than a third in 70% of patients with myelofibrosis.

Continue Reading
Advertisement

Trending